⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19751280 | 0.80 | — | — | |
| SCHEMBL30462442 | 0.78 | MEN1 (0.37) | — | |
| SCHEMBL4019745 | 0.78 | PHF8 (0.39) | — | |
| SCHEMBL5914371 | 0.77 | — | — | |
| SCHEMBL4000043 | 0.77 | ALDH1A1 (0.37) | — | |
| SCHEMBL26558 | 0.76 | — | — | |
| SCHEMBL18512277 | 0.76 | — | — | |
| SCHEMBL1445561 | 0.76 | — | — | |
| SCHEMBL6167668 | 0.76 | — | — | |
| SCHEMBL5317736 | 0.75 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 943 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286949-A | Perovskite ink, large-area perovskite thin film and battery device | 武汉理工大学 | 2022-11-04 | — | — | CN | claimed |
| CN-106659721-B | Process for the preparation of a medicament | 基因泰克公司 | 2021-01-01 | — | — | CN | claimed |
| CN-105061356-B | Synthesis method of 2-amino-5-arylthiazole | 上海瑞博化学有限公司 | 2020-06-26 | — | — | CN | claimed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | claimed |
| US-10611753-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2020-04-07 | — | — | US | claimed |
| EP-3129025-B1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH INC (US) | 2019-05-15 | — | — | EP | claimed |
| US-20180134685-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | claimed |
| US-20170022183-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2017-01-26 | — | — | US | claimed |
| EP-2753609-B1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2016-11-09 | — | — | EP | claimed |
| CN-105237384-A | Preparation method of polysubstituted fluorene derivative | SHANGHAI WANSHUO CHEMICAL CO LTD | 2016-01-13 | — | — | CN | claimed |
| US-20150336914-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | claimed |
| US-20150094346-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2015-04-02 | — | — | US | claimed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | claimed |
| WO-2013035047-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | claimed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | claimed |
| EP-0851850-B1 | SYNTHESIS OF ALPHA-CHLORO OR ALPHA-FLUORO KETONES | MERCK & CO INC (US) | 2001-12-12 | — | — | EP | claimed |
| EP-4747249-A1 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026103747-A1 | SALT OF THIAZOLE DERIVATIVE INHIBITOR, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103749-A1 | CRYSTAL FORM OF THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026099455-A1 | DIHYDROPYRROLOPYRIMIDINONE COMPOUNDS AS TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| EP-3599854-B1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORP (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616193-B2 | 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility | SPERMATECH AS (NO) | 2026-05-05 | — | — | US | disclosed |
| EP-4727934-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4711365-A1 | THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-12559507-B2 | Method for preparing an enantiomerically enriched form of 3-(2-chlorothiazol-5-yl)-8-methyl-7-oxo-6-phenyl-2,3-dihydrothiazolo[3,2-ajpyrimidin-4-ium-5-olate | BASF SE (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | disclosed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4676481-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-12516030-B2 | Preparation of 2-chloro-1-(2-chlorothiazol-5-yl)ethanone | BASF SE (DE) | 2026-01-06 | — | — | US | disclosed |
| EP-4665321-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | Atrogi AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4651867-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | Atrogi AB (SE) | 2025-11-26 | — | — | EP | disclosed |
| EP-4647426-A2 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2025-11-12 | — | — | EP | disclosed |
| US-12459953-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| WO-2025215082-A1 | FUSED AZINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4605393-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-08-27 | — | — | EP | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| EP-4594308-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | Vividion Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250243160-A1 | INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY | Automera PTE. LTD (SG) | 2025-07-31 | — | — | US | disclosed |
| US-12365657-B2 | Preparation of 2-chloro-1-(2-chlorothiazol-5-yl)ethanone | BASF SE (DE) | 2025-07-22 | — | — | US | disclosed |
| US-20250223294-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-07-10 | — | — | US | disclosed |
| US-20250206703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025129023-A1 | INDOLE AMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120077046-A | Triazole-substituted imidazo [1,2-A ] pyrimidines as CGAS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025076235-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250092053-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| US-12247033-B2 | Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| EP-4514794-A1 | FGFR2 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4504703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | Merck Sharp & Dohme LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119421882-A | FGFR2 inhibitor compounds | 伊莱利利公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250042856-A1 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | ATROGI AB (SE) | 2025-02-06 | — | — | US | disclosed |
| WO-2025022915-A1 | METHOD FOR PRODUCING 2-ETHYLSULFONYL-1-HETEROARYLETHANONE COMPOUND | 日本曹達株式会社 | 2025-01-30 | — | — | WO | disclosed |
| CN-114555568-B | Preparation of 2-chloro-1- (2-chlorothiazol-5-yl) ethanone | 巴斯夫欧洲公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2025017059-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024260929-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-12-24 | — | — | US | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-12-05 | — | — | US | disclosed |
| WO-2024235205-A1 | THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-12144349-B2 | Pesticidal mixtures comprising a mesoionic compound | BASF SE (DE) | 2024-11-19 | — | — | US | disclosed |
| EP-4444699-A1 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | Atrogi AB (SE) | 2024-10-16 | — | — | EP | disclosed |
| CN-115504920-B | Pyrrolidone and preparation method thereof | FMC公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2024184408-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-09-12 | — | — | WO | disclosed |
| US-20240287051-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| WO-2024170727-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | ATROGI AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| CN-118525019-A | Process for preparing ledipasvir | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-08-20 | — | — | CN | disclosed |
| CN-118525004-A | Crystalline forms of (R) -2- (tert-butylamino) -1- (5-fluoropyridin-3-yl) -ethan-1-ol hemitartrate for use in the treatment of hyperglycemia and type 2 diabetes | 阿托基公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240262816-A1 | METHOD FOR PREPARING ENANTIOMERICALLY ENRICHED 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE BY HYDROGENATION OF THE 2-OXO DERIVATIVE IN THE PRESENCE OF A CHIRAL TRANSITION METAL CATALYST | BASF SE (DE) | 2024-08-08 | — | — | US | disclosed |
| US-20240254143-A1 | OREXIN RECEPTOR AGONISTS AND USES THEREOF | APTUIT (VERONA) SRL (IT) | 2024-08-01 | — | — | US | disclosed |
| WO-2024153813-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | ATROGI AB (SE) | 2024-07-25 | — | — | WO | disclosed |
| EP-3494971-B1 | SALTS OF ERK INHIBITORS | GENENTECH INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228503-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-07-11 | — | — | US | disclosed |
| US-20240228503-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-07-11 | — | — | US | disclosed |
| US-20240228503-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-07-11 | — | — | US | disclosed |
| WO-2024110994-A1 | A PROCESS FOR THE PREPARATION OF LEDIPASVIR | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024083773-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-25 | — | — | WO | disclosed |
| EP-4352052-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| CN-117881676-A | Methods for preparing ERK inhibitors | 大塚制药株式会社 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240101575-A1 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE | BASF SE (DE) | 2024-03-28 | — | — | US | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334323-A1 | OREXIN RECEPTOR AGONISTS AND USES THEREOF | Jazz Pharmaceuticals Ireland Limited (IE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117616030-A | Orexin receptor agonists and uses thereof | 爵士制药爱尔兰有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240051929-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2024-02-15 | — | — | US | disclosed |
| CN-112771034-B | Heteroaryl azole compound and pest control agent | 日本曹达株式会社 | 2024-02-09 | — | — | CN | disclosed |
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4305032-A1 | 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-20230416273-A1 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE | BASF SE (DE) | 2023-12-28 | — | — | US | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117136188-A | Process for preparing enantiomerically enriched forms of 2- [2- (2-chlorothiazol-5-yl) -2-hydroxyethyl ] sulfanyl-6-hydroxy-3-methyl-5-phenylpyrimidin-4-one by hydrogenation of 2-oxo derivatives in the presence of chiral transition metal catalysts | 巴斯夫欧洲公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4038056-B1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023212535-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116917291-A | Process for preparing enantiomerically enriched forms of 3- (2-chlorothiazol-5-yl) -8-methyl-7-oxo-6-phenyl-2, 3-dihydrothiazolo [3,2-a ] pyrimidin-4-5-ol salts | 巴斯夫欧洲公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230322693-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2023-10-12 | — | — | US | disclosed |
| WO-2023192170-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192170-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-116783200-A | Process for preparing enantiomerically enriched forms of 3- (2-chlorothiazol-5-yl) -8-methyl-7-oxo-6-phenyl-2, 3-dihydrothiazolo [3,2-a ] pyrimidin-4-ium-5-alkoxide | 巴斯夫欧洲公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116745290-A | Process for preparing enantiomerically enriched forms of 2- [2- (2-chlorothiazol-5-yl) -2-hydroxyethyl ] sulfanyl-6-hydroxy-3-methyl-5-phenylpyrimidin-4-one | 巴斯夫欧洲公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| EP-4232449-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-110198928-B | Benzyloxy-pyridinyl-cyclopropanecarboxylic acid, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115286949-B | Perovskite ink, large-area perovskite film and battery device | 武汉理工大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-110177773-B | Benzyl aminopyridine cyclopropanecarboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2023-08-24 | — | — | US | disclosed |
| CN-110312706-B | Indanyl aminopyridyl cyclopropanecarboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225446-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4222145-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-111777594-B | Method for preparing a medicament | 基因泰克公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023105035-A1 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | ATROGI AB (SE) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023090345-A1 | METHOD FOR PRODUCING 2-ALKYLTHIO-1-IMIDAZOYLETHANONE COMPOUND | 日本曹達株式会社 | 2023-05-25 | — | — | WO | disclosed |
| US-20230159562-A1 | PYRIMIDINIUM COMPOUNDS AND THEIR MIXTURES FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2023-05-25 | — | — | US | disclosed |
| CN-116102580-A | Pyrimidinium compounds and mixtures thereof for combating animal pests | 巴斯夫欧洲公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116076518-A | Pyrimidinium compounds and mixtures thereof for combating animal pests | 巴斯夫欧洲公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116082366-A | Pyrimidinium compounds and mixtures thereof for combating animal pests | 巴斯夫欧洲公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116018339-A | Preparation of 2-chloro-1- (2-chlorothiazol-5-yl) ethanone | 巴斯夫欧洲公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20230097157-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| CN-110809467-B | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4142716-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | Spermatech AS (NO) | 2023-03-08 | — | — | EP | disclosed |
| CN-115768260-A | 5- (1H-indol-3-yl) -oxazole, -oxadiazole and-furan derivatives as sperm motility enhancers | 精液技术股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11578083-B2 | Pyrimidinium compounds and their mixtures for combating animal pests | BASF SE (DE) | 2023-02-14 | — | — | US | disclosed |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-01-26 | — | — | US | disclosed |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-01-26 | — | — | US | disclosed |
| US-11560367-B2 | Pyrrolidinones and a process to prepare them | FMC CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115504920-A | Pyrrolidone and preparation method thereof | FMC公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| WO-2022259222-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022233872-A1 | OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-11-10 | — | — | WO | disclosed |
| CN-115286949-A | Perovskite ink, large-area perovskite thin film and battery device | 武汉理工大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-110691516-B | Pyrrolidone and preparation method thereof | FMC公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20220340604-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2022-10-27 | — | — | US | disclosed |
| CN-110386927-B | Histone Acetyltransferase (HAT) inhibitors and uses thereof | 中国科学院上海药物研究所 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022187965-A1 | 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | adMare Therapeutics Society (CA) | 2022-09-15 | — | — | WO | disclosed |
| CN-110546153-B | Process for preparing optically active 2, 3-dihydrothiazolo [3,2-A ] pyrimidin-4-ium compounds | 巴斯夫欧洲公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-111377867-B | Intermediate for synthesizing 2- (1-alkyl-1H-pyrazol-4-yl) morpholine and preparation method and application thereof | 南京药石科技股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-111377867-B | Intermediate for synthesizing 2- (1-alkyl-1H-pyrazol-4-yl) morpholine and preparation method and application thereof | 南京药石科技股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-11420963-B2 | Rebamipide prodrugs, preparation method and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2022-08-23 | — | — | US | disclosed |
| WO-2022159746-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11357757-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2022-06-14 | — | — | US | disclosed |
| CN-110621677-B | Process for preparing chiral 2, 3-dihydrothiazolo [3,2-A ] pyrimidin-4-ium compounds | 巴斯夫欧洲公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109689630-B | Diaryl azole compound and pest control agent | 日本曹达株式会社 | 2022-06-03 | — | — | CN | disclosed |
| CN-114555568-A | Preparation of 2-chloro-1- (2-chlorothiazol-5-yl) ethanone | 巴斯夫欧洲公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220133703-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-05 | — | — | US | disclosed |
| WO-2022087326-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2022076621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3978504-A1 | CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDINE DERIVATIVES FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2022-04-06 | — | — | EP | disclosed |
| CN-105636936-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3475260-B1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | UNIV KONSTANZ (DE) | 2022-03-30 | — | — | EP | disclosed |
| CN-112689627-B | Tricyclic substituted piperidinediones | 南京明德新药研发有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | disclosed |
| EP-3971168-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-03-23 | — | — | EP | disclosed |
| EP-3514146-B1 | DIARYL- AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| CN-106083759-B | Brand-new synthesis process of lutofopa | 上海丸全化学科技有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20220033384-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20220033384-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20210380556-A1 | HETEROARYLAZOLE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210380556-A1 | HETEROARYLAZOLE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210368794-A1 | PESTICIDAL MIXTURES COMPRISING A MESOIONIC COMPOUND | BASF SE (DE) | 2021-12-02 | — | — | US | disclosed |
| EP-3601298-B1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3911629-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2021-11-24 | — | — | EP | disclosed |
| US-11180485-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-11180485-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-20210355139-A1 | Pyrimidinium Compounds and Their Mixtures for Combating Animal Pests | BASF SE (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3681872-B1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-11-17 | — | — | EP | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021220012-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2021-11-04 | — | — | WO | disclosed |
| EP-3615543-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| CN-113454063-A | 3-substituted phenylamidine compounds, preparation method and application thereof | PI工业有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-11124528-B2 | Process for preparing optically active 2,3-dihydrothiazolo[3,2-A]pyrimidin-4-ium compounds | BASF SE (DE) | 2021-09-21 | — | — | US | disclosed |
| EP-3878451-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND | Array Biopharma Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113387962-A | Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| EP-3862352-A1 | HETEROARYLAZOLE COMPOUND AND PEST CONTROL AGENT | Nippon Soda Co., Ltd. (JP) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021154997-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-11072611-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2021-07-27 | — | — | US | disclosed |
| US-11072611-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2021-07-27 | — | — | US | disclosed |
| US-11066389-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066389-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3573952-B1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3619217-B1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| US-11034703-B2 | Process for preparing chiral 2,3-dihydrothiazolo[3,2-A] pyrimidin-4-ium compounds | BASF SE (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028052-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2021-06-08 | — | — | US | disclosed |
| CN-112771034-A | Heteroaryl azole compound and pest control agent | 日本曹达株式会社 | 2021-05-07 | — | — | CN | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| CN-112689627-A | Tricyclic substituted piperidinediones | 南京明德新药研发有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20210107890-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORPORATION | 2021-04-15 | — | — | US | disclosed |
| CN-112645927-A | Process for the preparation of a medicament | 基因泰克公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| WO-2021063880-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2021-04-08 | — | — | WO | disclosed |
| US-10961196-B2 | Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor | Universität Konstanz (DE) | 2021-03-30 | — | — | US | disclosed |
| US-10961196-B2 | Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor | Universität Konstanz (DE) | 2021-03-30 | — | — | US | disclosed |
| US-20210087207-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2021-03-25 | — | — | US | disclosed |
| EP-3544958-B1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| EP-3461816-B1 | FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10919859-B2 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
| US-10913720-B2 | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210030731-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-02-04 | — | — | US | disclosed |
| EP-3466953-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| EP-3227297-B1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3760630-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760630-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2021-01-06 | — | — | EP | disclosed |
| CN-106659721-B | Process for the preparation of a medicament | 基因泰克公司 | 2021-01-01 | — | — | CN | disclosed |
| US-10875838-B2 | Pyrrolidinones and a process to prepare them | FMC CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| CN-111777594-A | Process for the preparation of a medicament | 基因泰克公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3269716-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3269716-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200239466-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-30 | — | — | US | disclosed |
| US-20200239466-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-30 | — | — | US | disclosed |
| WO-2020148617-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2020-07-23 | — | — | WO | disclosed |
| CN-111377867-A | Intermediate for synthesizing 2- (1-alkyl-1H-pyrazol-4-yl) morpholine and preparation method and application thereof | 南京药石科技股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111377867-A | Intermediate for synthesizing 2- (1-alkyl-1H-pyrazol-4-yl) morpholine and preparation method and application thereof | 南京药石科技股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-105061356-B | Synthesis method of 2-amino-5-arylthiazole | 上海瑞博化学有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-105061356-B | Synthesis method of 2-amino-5-arylthiazole | 上海瑞博化学有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-106187942-B | Benzothiazolone compounds | 诺华股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111315726-A | Heteroaryl substituted β -hydroxyethylamines for the treatment of hyperglycemia | 阿托基公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| CN-107278203-B | 4, 6-substituted pyrazolo [1,5-a ] pyrazines as JANUS kinase inhibitors | 阵列生物制药公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-2343298-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| CN-111031798-A | Method for controlling rice pests in rice | 巴斯夫欧洲公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2020071304-A1 | HETEROARYLAZOLE COMPOUND AND PEST CONTROL AGENT | 日本曹達株式会社 | 2020-04-09 | — | — | WO | disclosed |
| WO-2020071304-A1 | HETEROARYLAZOLE COMPOUND AND PEST CONTROL AGENT | 日本曹達株式会社 | 2020-04-09 | — | — | WO | disclosed |
| US-10611753-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611753-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2020058010-A1 | PESTICIDAL MIXTURES COMPRISING A MESOIONIC COMPOUND | BASF SE (DE) | 2020-03-26 | — | — | WO | disclosed |
| US-20200079800-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3619217-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2020-03-11 | — | — | EP | disclosed |
| EP-3615543-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615019-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200062773-A1 | 4,4a,5,7-TETRAHYDRO-3H-FURO[3,4-b]PYRIDINYL COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-20200055872-A1 | Process for Preparing Optically Active 2,3-Dihydrothiazolo[3,2-A]pyrimidin-4-ium Compounds | BASF SE (DE) | 2020-02-20 | — | — | US | disclosed |
| CN-110809467-A | Modulators of SESTRIN-GATOR2 interaction and uses thereof | 纳维托制药有限公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-3601298-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-3599854-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110691516-A | Pyrrolidone and preparation method thereof | FMC公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-110621677-A | Process for preparing chiral 2, 3-dihydrothiazolo [3,2-A ] pyrimidin-4-ium compounds | 巴斯夫欧洲公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-110546153-A | process for preparing optically active 2, 3-dihydrothiazolo [3,2-A ] pyrimidin-4-ium compounds | BASF SE | 2019-12-06 | — | — | CN | disclosed |
| US-20190352266-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-11-21 | — | — | US | disclosed |
| WO-2019201291-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | 中国科学院上海药物研究所 | 2019-10-24 | — | — | WO | disclosed |
| EP-3544958-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10421727-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2019-09-24 | — | — | US | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3535271-A1 | 4,4A,5,7-TETRAHYDRO-3H-FURO[3,4-B]PYRIDINYL COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2019-09-11 | — | — | EP | disclosed |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3514146-A1 | DIARYL AZOLE COMPOUND AND PESTICIDE | Nippon Soda Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190218183-A1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | Universität Konstanz (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190218183-A1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | Universität Konstanz (DE) | 2019-07-18 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190185459-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185459-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-3494971-A1 | SALTS OF ERK INHIBITORS | Genentech, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169184-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169184-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-06-06 | — | — | US | disclosed |
| EP-3129025-B1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3129025-B1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190125750-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2019-05-02 | — | — | US | disclosed |
| EP-3475260-A1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | Universität Konstanz (DE) | 2019-05-01 | — | — | EP | disclosed |
| EP-3466953-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10251868-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| EP-3461816-A1 | FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2019043183-A1 | METHOD OF CONTROLLING RICE PESTS IN RICE | BASF SE (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180351104-A1 | 3-SUBSTITUTED TELLUROPHENES AND RELATED COMPOUNDS | GOVERNING COUNCIL UNIV TORONTO (CA) | 2018-12-06 | — | — | US | disclosed |
| EP-2940024-B1 | BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2018-12-05 | — | — | EP | disclosed |
| CN-108929333-A | The method for preparing benzo oxygen azepine * compound | 豪夫迈·罗氏有限公司 | 2018-12-04 | — | — | CN | disclosed |
| US-10144849-B2 | Polishing composition and polishing method using the same | FUJIMI INCORPORATED (JP) | 2018-12-04 | — | — | US | disclosed |
| US-20180338978-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE HOLDINGS CORPORATION | 2018-11-29 | — | — | US | disclosed |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-3404032-A2 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-10125132-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2018-11-13 | — | — | US | disclosed |
| US-10125101-B2 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-13 | — | — | US | disclosed |
| WO-2018202654-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2018-11-08 | — | — | WO | disclosed |
| WO-2018200625-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018197541-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2018-11-01 | — | — | WO | disclosed |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018177970-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2018-10-04 | — | — | WO | disclosed |
| EP-3184526-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2018175226-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORPORATION (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-2970255-B9 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-09-19 | — | — | EP | disclosed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| EP-3364958-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2855478-B1 | LEDIPASVIR D-TARTRATE | GILEAD PHARMASSET LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2855478-B1 | LEDIPASVIR D-TARTRATE | GILEAD PHARMASSET LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018138029-A1 | BENZYLOXYPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018138027-A1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018095877-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | WO | disclosed |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-9974790-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974790-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| CN-105377856-B | Process for preparing benzoxazepine compounds | 豪夫迈·罗氏有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-20180134685-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134685-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134685-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9944618-B2 | Inhibiting neurotransmitter reuptake | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-04-17 | — | — | US | disclosed |
| WO-2018052035-A1 | DIARYL AZOLE COMPOUND AND PESTICIDE | 日本曹達株式会社 | 2018-03-22 | — | — | WO | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3269716-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2018-01-17 | — | — | EP | disclosed |
| EP-3269716-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009790-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF HCV INHIBITOR | VETUKURI PRASAD RAJU VNKV (IN) | 2018-01-11 | — | — | US | disclosed |
| WO-2017220205-A1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | Universität Konstanz (DE) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369447-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-12-28 | — | — | US | disclosed |
| EP-3260445-A1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | Universität Konstanz (DE) | 2017-12-27 | — | — | EP | disclosed |
| EP-3260445-A1 | COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR | Universität Konstanz (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-20170362227-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-12-21 | — | — | US | disclosed |
| US-20170362227-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-12-21 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362227-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-12-21 | — | — | US | disclosed |
| US-9840471-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170327488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| EP-3243817-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2017-11-15 | — | — | EP | disclosed |
| EP-2688891-B1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9814722-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814722-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3227297-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2970255-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-08-02 | — | — | EP | disclosed |
| EP-2970255-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-08-02 | — | — | EP | disclosed |
| US-9718807-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718807-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718807-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2890687-B1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9682987-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682987-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682987-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670204-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2017-06-06 | — | — | US | disclosed |
| US-9670204-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2017-06-06 | — | — | US | disclosed |
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2961391-B1 | FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9623012-B2 | Formulation comprising benzothiazolone compound | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2017-03-16 | — | — | US | disclosed |
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2017-03-16 | — | — | US | disclosed |
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2348023-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-3129025-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | Genentech, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022183-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022183-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022183-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9527877-B2 | Metal complexes, their application and methods of carrying out of metathesis reaction | APEIRON SYNTHESIS S.A. (PL) | 2016-12-27 | — | — | US | disclosed |
| US-9527877-B2 | Metal complexes, their application and methods of carrying out of metathesis reaction | APEIRON SYNTHESIS S.A. (PL) | 2016-12-27 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160346286-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-20160346286-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-20160340345-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340345-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340345-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| CN-106117187-A | A kind of hepatitis C virus inhibitors, pharmaceutical composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-2753609-B1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| EP-2474545-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2426129-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2455382-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| CN-105992761-A | Optically active compounds having thrombopoietin receptor agonism and process for preparing intermediates thereof | 盐野义制药株式会社 | 2016-10-05 | — | — | CN | disclosed |
| US-20160279107-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-2744499-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272648-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2016-09-22 | — | — | US | disclosed |
| US-20160272648-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2016-09-22 | — | — | US | disclosed |
| EP-2790511-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160244443-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-08-25 | — | — | US | disclosed |
| US-20160244443-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-08-25 | — | — | US | disclosed |
| US-20160244443-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-08-25 | — | — | US | disclosed |
| US-9416144-B2 | Benzoxazine oxazolidinone compound, preparation method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9416144-B2 | Benzoxazine oxazolidinone compound, preparation method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9416144-B2 | Benzoxazine oxazolidinone compound, preparation method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-08-16 | — | — | US | disclosed |
| CN-103214484-B | Pyrrolo-[2,3-b] pyridine replaced as the heteroaryl of Janus inhibitors of kinases and pyrrolo-[2,3-b] pyrimidine | 因塞特控股公司 | 2016-07-06 | — | — | CN | disclosed |
| WO-2016103232-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF HCV INHIBITOR | GRANULES INDIA LIMITED (IN) | 2016-06-30 | — | — | WO | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| WO-2016090285-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2855454-B1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2855454-B1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-3019478-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2633289-B1 | USE OF SIGNAL ENHANCING COMPOUNDS IN ELECTROCHEMILUMINESCENCE DETECTION | ROCHE DIAGNOSTICS GMBH (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2711368-B1 | Benzoxazepin PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20160075670-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2016-03-17 | — | — | US | disclosed |
| CN-103539769-B | As the macrocylc compound of kinase inhibitor and HSP90 inhibitor | Univerisity of Strasbourg (FR) | 2016-03-16 | — | — | CN | disclosed |
| CN-105377856-A | Process for preparing benzoxazepine compounds | HOFFMANN LA ROCHE | 2016-03-02 | — | — | CN | disclosed |
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9249141-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9249141-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9249141-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160024044-A1 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2016-01-28 | — | — | US | disclosed |
| EP-2350077-B1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS LTD (GB) | 2016-01-27 | — | — | EP | disclosed |
| CN-102245605-B | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2016-01-27 | — | — | CN | disclosed |
| WO-2016009297-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970255-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970329-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| CN-105237384-A | Preparation method of polysubstituted fluorene derivative | SHANGHAI WANSHUO CHEMICAL CO LTD | 2016-01-13 | — | — | CN | disclosed |
| US-20160002261-A1 | Process | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | US | disclosed |
| US-20160000761-A1 | Formulation comprising benzothiazolone compound | NOVARTIS AG (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20150376136-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2958897-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | ENTASIS THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9206187-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase | INCYTE HOLDINGS CORPORATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206187-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase | INCYTE HOLDINGS CORPORATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150344488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150336914-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336984-A1 | BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-26 | — | — | US | disclosed |
| US-20150336984-A1 | BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-26 | — | — | US | disclosed |
| US-20150336984-A1 | BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-26 | — | — | US | disclosed |
| EP-2343299-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2940024-A1 | BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-11-04 | — | — | EP | disclosed |
| EP-2940024-A1 | BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-20150295178-A1 | 3-SUBSTITUTED TELLUROPHENES AND RELATED COMPOUNDS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-10-15 | — | — | US | disclosed |
| WO-2015154674-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015154674-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| CN-104968337-A | Formulation comprising benzothiazolone compound | NOVARTIS AG | 2015-10-07 | — | — | CN | disclosed |
| CN-103131330-B | Composition for polishing and use its Ginding process | FUJIMI INC. (JP) | 2015-09-23 | — | — | CN | disclosed |
| US-9139570-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139570-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139570-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150238492-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-20150238492-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2015-08-20 | — | — | US | disclosed |
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2015-08-20 | — | — | US | disclosed |
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2015-08-20 | — | — | US | disclosed |
| US-9090628-B2 | Benzoxazepin compounds selective for PI3K P110 delta and methods of use | GENENTECH, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9079912-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079912-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2890687-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-9062070-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9056860-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056860-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056860-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-06-16 | — | — | US | disclosed |
| CN-104662004-A | Novel rebamipide prodrug, method for producing same, and usage thereof | SAMJIN PHARM CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-9040528-B2 | Chemical compounds 542 | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| US-20150141659-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141659-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141659-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150126744-A1 | Metal Complexes, Their Application and Methods of Carrying out of Metathesis Reaction | APEIRON SUNTHESIS S.A. (PL) | 2015-05-07 | — | — | US | disclosed |
| US-20150126744-A1 | Metal Complexes, Their Application and Methods of Carrying out of Metathesis Reaction | APEIRON SUNTHESIS S.A. (PL) | 2015-05-07 | — | — | US | disclosed |
| EP-2348023-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2343298-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2865669-A1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2015-04-29 | — | — | EP | disclosed |
| US-20150111872-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111872-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111872-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-04-23 | — | — | US | disclosed |
| EP-2855454-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | Gilead Pharmasset LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855478-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | Gilead Pharmasset LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20150094346-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2015-04-02 | — | — | US | disclosed |
| US-8993590-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2015-03-31 | — | — | US | disclosed |
| US-8993590-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2015-03-31 | — | — | US | disclosed |
| US-8993590-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2015-03-31 | — | — | US | disclosed |
| US-8969588-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969588-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969588-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8946245-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946245-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| US-8933108-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933086-B2 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933086-B2 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933242-B2 | Metal complexes, their application and methods of carrying out of metathesis reaction | APEIRON SYNTHESIS S.A. (PL) | 2015-01-13 | — | — | US | disclosed |
| US-8933242-B2 | Metal complexes, their application and methods of carrying out of metathesis reaction | APEIRON SYNTHESIS S.A. (PL) | 2015-01-13 | — | — | US | disclosed |
| US-20140364601-A1 | PROCESS | ASTRAZENECA AB (SE) | 2014-12-11 | — | — | US | disclosed |
| US-8889722-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8889722-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8889722-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| EP-2184279-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | SHIONOGI & CO (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2184279-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | SHIONOGI & CO (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2790511-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140303140-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-10-09 | — | — | US | disclosed |
| US-20140303140-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014159251-A2 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014139882-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139882-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8829185-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140243360-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243360-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130582-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-07-24 | — | — | US | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2744499-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8754099-B2 | Oxadiazole beta carboline derivatives as antidiabetic compounds | MERCK SHARP & DOHME CORP (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | ASTRAZENECA AB (SE) | 2014-05-08 | — | — | US | disclosed |
| WO-2014067016-A1 | 3-SUBSTITUTED TELLUROPHENES AND RELATED COMPOUNDS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2014-05-08 | — | — | WO | disclosed |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. | 2014-04-17 | — | — | US | disclosed |
| WO-2014059185-A1 | AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-2707362-A1 | PROCESS | AstraZeneca AB (SE) | 2014-03-19 | — | — | EP | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2014033654-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8658641-B2 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2014-02-25 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2014013076-A1 | HEXAHYDROPYRROLOTHIAZINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-23 | — | — | WO | disclosed |
| EP-1957077-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| WO-2014001109-A1 | METAL COMPLEXES, THEIR APPLICATION AND METHODS OF CARRYING OUT OF METATHESIS REACTION | APEIRON SYNTHESIS S.A. (PL) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005210-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2013184702-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| WO-2013184698-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| US-20130324496-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2013-12-05 | — | — | US | disclosed |
| US-20130324740-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2406233-B1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8541425-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-8530485-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530485-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530668-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530668-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530668-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | SHIONOGI & CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | SHIONOGI & CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | SHIONOGI & CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013035047-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013028474-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-8343955-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8329683-B2 | Treatment of neurofibromatosis with radicicol and its derivatives | NEXGENIX PHARMACEUTICALS, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329683-B2 | Treatment of neurofibromatosis with radicicol and its derivatives | NEXGENIX PHARMACEUTICALS, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2012156693-A1 | PROCESS | ASTRAZENECA AB (SE) | 2012-11-22 | — | — | WO | disclosed |
| EP-2523558-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264777-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8278316-B2 | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012126901-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2474545-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165314-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2465505-A1 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Bayer HealthCare LLC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2455382-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2426129-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2406233-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-29 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| EP-1966202-B1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110223210-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20110223210-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20110224157-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20110224157-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| EP-2350077-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2348023-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011088025-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343298-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-1848709-B1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LTD (GB) | 2011-05-18 | — | — | EP | disclosed |
| EP-1848709-B1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LTD (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100301014-A1 | Polishing Composition and Polishing Method Using the Same | FUJIMI INCORPORATED (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2010-10-21 | — | — | US | disclosed |
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2010-10-21 | — | — | US | disclosed |
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2010-10-21 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-2237311-A1 | POLISHING COMPOSITION AND POLISHING METHOD USING THE SAME | FUJIMI INCORPORATED (JP) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010104818-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100184799-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| EP-2184279-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2184279-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2178537-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010043893-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-7632861-B2 | 1-Isobenzofuranethanamine, 1-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-1,3-dihydro-N,N-dimethyl-; use in treating a disorder associated with aberrant levels of tachykinins or serotonin; nerve system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2104503-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2009-09-30 | — | — | EP | disclosed |
| WO-2009111540-A1 | METHODS FOR PREPARING PYRIDYLETHYL-SUBSTITUTED CARBOLINES | MEDIVATION NEUROLOGY, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009103478-A1 | PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-7576081-B2 | Central nervous system disorders ; sexual disorders; hypotensive agents; analgesics; neurodegenerative disease; obesity; Alzheimer's disease; obsessive compulsive disorders; antidepressants | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009064684-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124613-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-20090124613-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2009011836-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008150302-A1 | TREATMENT OF NEUROFIBROMATOSIS WITH RADICICOL AND ITS DERIVATIVES | NEXGENIX PHARMACEUTICALS (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1954287-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| US-7375100-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1633714-B1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| EP-1633715-B1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LTD (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007034278-A2 | FUSED IMIDAZOLE DERIVATIVES AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| US-7067541-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1633714-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633715-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633729-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | VAN DER GRAAF PIETER H | 2006-03-09 | — | — | US | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1572214-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-6942966-B1 | libraries formed by permutations; combinatorial chemistry; drug screening | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-6900216-B2 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108675-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
| EP-1467999-A1 | OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1078924-B1 | Intermediates and a process for producing beta-adrenergic receptor agonists | PFIZER PROD INC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1463508-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2004-10-06 | — | — | EP | disclosed |
| US-6800444-B1 | USEFUL AS ANTIBACTERIAL AND OTHER PHARMACEUTICAL AGENTS/INTERMEDIATES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6660466-B1 | Reacting reactive appendage compounds such as meta benzylic compounds or alpha-amide compounds with scaffold molecules having reactive functionalities and contacting the intermediate library with a reducing agent | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| WO-2003059912-A1 | OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| US-6559303-B1 | Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical | ISIS PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1065206-B1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6441181-B1 | MAKING (4-(2-(2-(6-AMINOPYRIDIN-3-YL)-2(R)-HYDROXYETHYLAMINO)ETHOXY) PHENYLACETIC ACID; DEPROTECTION OF PYRROLE DERIVATIVE; INTERMEDIATES | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020045757-A1 | Compound and process for producing beta-adrenergic receptor agonist | SCOTT ROBERT W (US) | 2002-04-18 | — | — | US | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-0851850-B1 | SYNTHESIS OF ALPHA-CHLORO OR ALPHA-FLUORO KETONES | MERCK & CO INC (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0851850-B1 | SYNTHESIS OF ALPHA-CHLORO OR ALPHA-FLUORO KETONES | MERCK & CO INC (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6329523-B1 | FOR ANTIBACTERIAL PHARMACEUTICAL USE, USEFUL FOR IDENTIFYING METAL CHELATING SPECIES FOR ?HEAVY METAL? THERAPY; IMAGING AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-0931079-B1 | SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORP (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6297382-B1 | (4-(2-(2-(6-AMINOPYRIDIN-3-YL)-2(R)-HYDROXYETHYLAMINO)ETHOXY) PHENYLACETIC ACID, | PFIZER, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0823896-B1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2001-07-11 | — | — | EP | disclosed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | disclosed |
| US-6197965-B1 | POLYARYLALKYLAMINO-SUBSTITUED PYRIDINE DERIVATIVES; DRUGS, MEDICINE, DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| EP-1078924-A1 | Intermediates and a process for producing beta-adrenergic receptor agonists | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1054881-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6150129-A | USEFUL AS ANTIBACTERIAL AND OTHER PHARMACEUTICAL AGENTS AND AS INTERMEDIATES FOR PREPARATION OF OTHER PHARMACEUTICAL AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-0817787-A4 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-6040305-A | ENZYME INHIBITOR AS ANTITUMOR AGENT TREATING PANCREATIC TUMOR, LUNG CANCER, MYELOID LEUKEMIA, THYROID FOLLICULAR TUMOR, MYELODYSPLASTIC TUMOR, EPIDERMAL CARCINOMA TUMOR, BLADDER TUMOR, COLON TUMOR, BREAST TUMOR, PROSTATE TUMOR | SCHERING CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| US-5998419-A | BACTERICIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0931079-A1 | SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
| US-5922872-A | BACTERICIDES AND DRUGS | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999032475-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5840725-A | Substituted oximes, hydrazones and olefins as neurokinin antagonists | SCHERING CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5817489-A | BACTERICIDES, OR CHEMICAL INTERMEDIATES THEREOF; DRUG LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817651-A | ANALGESICS, RHEUMATIC DISEASES, ANTIINFLAMMATORY AGENTS | SANOFI (FR) | 1998-10-06 | — | — | US | disclosed |
| US-5798360-A | ANTIBACTERIAL AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5786515-A | Synthesis of α-chloro or fluoro ketones | MERCK & CO., INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5786515-A | Synthesis of α-chloro or fluoro ketones | MERCK & CO., INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5780241-A | ALTERING ELECTROCHEMICAL PROPERTIES BY DECYCLIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0851850-A1 | SYNTHESIS OF $g(a)-CHLORO OR FLUORO KETONES | Merck & Co., Inc. (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0851850-A1 | SYNTHESIS OF $g(a)-CHLORO OR FLUORO KETONES | Merck & Co., Inc. (US) | 1998-07-08 | — | — | EP | disclosed |
| WO-1998028280-A1 | CERTAIN 3-[2,4-DISUBSTITUTED-5-(SUBSTITUTED AMINO)PHENYL]-1-SUBSTITUTED-6-TRIFLUOROMETHYL-2,4-(1H,3H)-PYRIMIDINEDIONE DERIVATIVES AS HERBICIDES | FMC CORPORATION (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998020349-A1 | COMPLEX CHEMICAL LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5731438-A | BACTERICIDES; DRUGS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1998011099-A1 | SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0823896-A1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1998005332-A1 | NOVEL HETEROCYCLE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5696267-A | ANTIHISTAMINES; ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| WO-1997010195-A1 | SYNTHESIS OF α-CHLORO OR FLUORO KETONES | MERCK & CO., INC. (US) | 1997-03-20 | — | — | WO | disclosed |
| WO-1997010195-A1 | SYNTHESIS OF α-CHLORO OR FLUORO KETONES | MERCK & CO., INC. (US) | 1997-03-20 | — | — | WO | disclosed |
| US-5607933-A | METHODS FOR TREATMENT OF GLAUCOMA AND FOR RELIEF OF PAIN AND RHEUMATIC AND INFLAMMATORY CONDITIONS BY ADMINISTERING THE INDOLES; N-HETERYL IS 2-PIPERAZINYL | STERLING WINTHROP INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996034857-A1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
| US-5324737-A | Analgesics, antirheumatic and antiinflammatory agents, glaucoma | STERLING WINTHROP INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | disclosed |
| US-5068234-A | Analgesics, rheumatic diseases, antiinflammatory agents or antiglaucoma | STERLING DRUG INC. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0444451-A2 | 3-Arylcarbonyl-1H-indoles useful as therapeutic agents | STERLING WINTHROP INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-4408055-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-10-04 | — | — | US | disclosed |
| US-4385177-A | Cephalosporins having a carbamoylalkoxyiminoarylacetamido group at 7-position | GLAXO LABORATORIES, LTD. (GB) | 1983-05-24 | — | — | US | disclosed |
| US-4385177-A | Cephalosporins having a carbamoylalkoxyiminoarylacetamido group at 7-position | GLAXO LABORATORIES, LTD. (GB) | 1983-05-24 | — | — | US | disclosed |